What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Enzyme
His scientific interests lie mostly in Internal medicine, Endocrinology, Plasminogen activator, Plasminogen activator inhibitor-1 and Myocardial infarction.
His Internal medicine research focuses on Cardiology and how it relates to ACE inhibitor.
The various areas that Douglas E. Vaughan examines in his Endocrinology study include Bradykinin and Enzyme inhibitor.
He works mostly in the field of Plasminogen activator, limiting it down to topics relating to Plasmin and, in certain cases, Angiotensin Receptor Antagonists, as a part of the same area of interest.
His research integrates issues of Insulin resistance, Luciferase, Fibrinolysis, Rasm and Sp1 transcription factor in his study of Plasminogen activator inhibitor-1.
His studies examine the connections between Myocardial infarction and genetics, as well as such issues in Risk factor, with regards to Disease, Cohort, Statistical significance, Relative risk and Endogeny.
His most cited work include:
- Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. (1003 citations)
- Angiotensin-Converting Enzyme Inhibitors (697 citations)
- Endogenous tissue-type plasminogen activator and risk of myocardial infarction (551 citations)
What are the main themes of his work throughout his whole career to date?
Douglas E. Vaughan focuses on Internal medicine, Endocrinology, Plasminogen activator, Plasminogen activator inhibitor-1 and Fibrinolysis.
Much of his study explores Internal medicine relationship to Cardiology.
His research in Endocrinology tackles topics such as Bradykinin which are related to areas like Vasodilation and Sodium nitroprusside.
His Plasminogen activator research incorporates themes from Plasmin, Tissue plasminogen activator, Biochemistry, Fibrosis and In vivo.
His Plasminogen activator inhibitor-1 research focuses on subjects like Molecular biology, which are linked to Gene expression.
His Myocardial infarction research is multidisciplinary, incorporating elements of Stroke volume and Heart failure.
He most often published in these fields:
- Internal medicine (66.37%)
- Endocrinology (50.15%)
- Plasminogen activator (39.82%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (66.37%)
- Plasminogen activator (39.82%)
- Plasminogen activator inhibitor-1 (30.97%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Plasminogen activator, Plasminogen activator inhibitor-1, Endocrinology and Cancer research.
Internal medicine is closely attributed to Cardiology in his research.
His Plasminogen activator research integrates issues from Senescence, Cell biology, Tissue homeostasis, Urine and Induced pluripotent stem cell.
His work deals with themes such as Nonalcoholic fatty liver disease, Metabolic syndrome, Allele and Pathogenesis, which intersect with Plasminogen activator inhibitor-1.
Douglas E. Vaughan works mostly in the field of Endocrinology, limiting it down to concerns involving Antagonist and, occasionally, Triglyceride.
His Cancer research study integrates concerns from other disciplines, such as Immunology, Gene mutation and Fibrosis, Pulmonary fibrosis, Cardiac fibrosis.
Between 2014 and 2021, his most popular works were:
- MiR-125b Is Critical for Fibroblast-to-Myofibroblast Transition and Cardiac Fibrosis. (117 citations)
- Molecular and physiological manifestations and measurement of aging in humans. (116 citations)
- Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence. (75 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Internal medicine
- Enzyme
His primary areas of investigation include Senescence, Cancer research, Cardiac fibrosis, Plasminogen activator inhibitor-1 and Fibrosis.
His research on Cancer research also deals with topics like
- microRNA, Myofibroblast, Wound healing, Tissue homeostasis and Matrix metalloproteinase most often made with reference to Fibroblast,
- Pathology and related In vivo, Pharmacology, Multiple sclerosis, Encephalomyelitis and Fingolimod.
His Plasminogen activator inhibitor-1 research is classified as research in Plasminogen activator.
The concepts of his Fibrosis study are interwoven with issues in Angiotensin II, Extracellular matrix and Epigenetics.
Douglas E. Vaughan is researching Circadian rhythm as part of the investigation of Endocrinology and Internal medicine.
Douglas E. Vaughan works in the field of Internal medicine, namely Urokinase.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
